Sun Pharmaceutical Industries Inc, the fully owned US subsidiary of Sun Pharmaceuticals, has acquired US-based drug ingredients manufacturer Chattem Chemicals for an undisclosed amount.
The company was acquired from Elcat Inc. Chattem is registered with the US Drug Enforcement Administration (DEA) as a narcotic raw material importer. For the year ending June 2008, Chattem is estimated to have sales of $26 million in a controlled substance market worth $6 billion of formulation products. The import registration of the company includes four controlled substance products listed in Schedule 2, such as methamphetamine, phenylacetone, raw opium and concentrate poppy straw. Additionally, it is also licensed by the DEA to manufacture Schedule 1 to 5 controlled substances.
At its facility spread over 6.5 acres in Chattanooga, Tennessee, Chattem employees 60 people and manufactures a variety of active pharmaceutical ingredients (APIs) with focus on controlled substances.
“This acquisition gets us a narcotic import registration as well as a fully operational USFDA and DEA approved API facility, with an expert team and approved, active drug master file (DMFs),” a Sun Pharma statement said. Chattem has 10 DMFs.
This is Sun Pharma?s third acquisition of a controlled substance business and it ?reflects our strategic resolve to be a more active player in the pain management segment in the US,” said Dilip Shanghvi, CMD, Sun Pharma.